Cellular Biomedicine Group, Inc. (CBMG) Analysts See $-0.47 EPS; R F Industries LTD (RFIL)’s Sentiment Is 1.75

April 17, 2018 - By Hazel Jackson

RF Industries, Ltd. (NASDAQ:RFIL) Logo

Analysts expect Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) to report $-0.47 EPS on May, 14.They anticipate $0.04 EPS change or 9.30% from last quarter’s $-0.43 EPS. After having $-0.48 EPS previously, Cellular Biomedicine Group, Inc.’s analysts see -2.08% EPS growth. The stock decreased 1.67% or $0.35 during the last trading session, reaching $20.6. About 18,774 shares traded. Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) has risen 64.04% since April 17, 2017 and is uptrending. It has outperformed by 52.49% the S&P500.

R F Industries LTD (RFIL) investors sentiment increased to 1.75 in Q4 2017. It’s up 0.75, from 1 in 2017Q3. The ratio increased, as 7 investment professionals opened new and increased positions, while 4 cut down and sold their holdings in R F Industries LTD. The investment professionals in our database now hold: 1.71 million shares, down from 1.90 million shares in 2017Q3. Also, the number of investment professionals holding R F Industries LTD in top ten positions was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 3 Increased: 4 New Position: 3.

Thompson Davis & Co. Inc. holds 0.22% of its portfolio in RF Industries, Ltd. for 35,000 shares. Acadian Asset Management Llc owns 574 shares or 0% of their US portfolio. Moreover, Blackrock Inc. has 0% invested in the company for 347,363 shares. The Texas-based Bridgeway Capital Management Inc has invested 0% in the stock. California Public Employees Retirement System, a California-based fund reported 40,400 shares.

The stock decreased 4.20% or $0.252 during the last trading session, reaching $5.748. About 129,488 shares traded. RF Industries, Ltd. (RFIL) has risen 193.55% since April 17, 2017 and is uptrending. It has outperformed by 182.00% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 8 sales for $791,159 activity.

RF Industries, Ltd., together with its subsidiaries, designs, makes, and markets interconnect products and systems to co-location centers, data processing centers, telecommunications and telephone companies, wireless carriers, and telecommunication equipment and solution providers in the United States and internationally. The company has market cap of $51.58 million. The companyÂ’s Connector and Cable Assembly division designs, makes, and distributes coaxial connectors and cable assemblies that are integrated with coaxial connectors. It has a 49.55 P/E ratio. The Company’s Cables Unlimited division makes and sells custom and standard cable assemblies, hybrid fiber optic power solution cables, adapters, and electromechanical wiring harnesses for communication, computer, LAN, automotive, and medical equipment.

Investors sentiment increased to 0.71 in Q4 2017. Its up 0.46, from 0.25 in 2017Q3. It is positive, as 4 investors sold Cellular Biomedicine Group, Inc. shares while 3 reduced holdings. 1 funds opened positions while 4 raised stakes. 472,598 shares or 15.99% less from 562,538 shares in 2017Q3 were reported. Blackrock Inc reported 0% of its portfolio in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). 453 are held by Tower Rech Capital Ltd (Trc). Geode Cap Mngmt Ltd Company invested in 0% or 40,805 shares. Zurcher Kantonalbank (Zurich Cantonalbank) owns 10,041 shares or 0% of their US portfolio. Meeder Asset Mngmt invested in 0% or 549 shares. Millennium Mgmt Ltd Com owns 102,516 shares or 0% of their US portfolio. Moreover, Northern has 0% invested in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) for 30,904 shares. California Employees Retirement Sys holds 19,000 shares. The Germany-based Deutsche Fincl Bank Ag has invested 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Morgan Stanley holds 0% or 1,300 shares. Bnp Paribas Arbitrage stated it has 7 shares. Barclays Public Ltd Co reported 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Moreover, Dimensional Fund Lp has 0% invested in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Vanguard Grp holds 0% or 83,071 shares in its portfolio. Bridgeway Capital reported 69,100 shares.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. The company has market cap of $350.02 million. It focuses on developing and marketing cell therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. It currently has negative earnings. The firm develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy.

RF Industries, Ltd. (NASDAQ:RFIL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.